Allergy Therapeutics PLC Hardman Research: Growth in a tough market
February 02 2018 - 2:15AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
02 February 2018
Hardman Research: Growth in a tough market
Growth in a tough market: AGY is a long-established specialist
in the prevention, diagnosis and treatment of allergies. Pollinex
Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT),
continues to gain market share despite being available in the EU
only on a 'Named Patient' basis. Trials designed to obtain
regulatory approval for PQ approved as a biologic in both Europe
and the US are well advanced. Meanwhile, although underlying sales
growth was weaker than expected in 1H'18, this was on the back of
an unusually shorter and lower pollen season in central Europe,
suggesting that AGY has continued to make further market share
gains.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/02.02.18-growth-in-a-tough-market.pdf
To contact us: Contacts: mh@hardmanandco.com
Hardman & Co Dr Martin dmh@hardmanandco.com
35 New Broad Street Hall gp@hardmanandco.com
London Dr Dorothea
EC2M 1NH Hill
www.hardmanandco.com Dr Gregoire
Follow us on Twitter Pave
@HardmanandCo
+44 20 7194
7622
About Hardman & Co: For the past 21 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFKDDKFBKDCBK
(END) Dow Jones Newswires
February 02, 2018 02:15 ET (07:15 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024